Trial · NCT00537238
Results by group80
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 80
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Participants With Response to Treatment | Pregabalin | 0.59 | proportion of participants | ||
| Proportion of Participants With Response to Treatment | Levetiracetam | 0.59 | proportion of participants | ||
| Percent Change From Baseline in 28 Day Seizure Frequency at Week 16 | Pregabalin | -53.93 | Full Range -100.0 to 533.1 | percent change | |
| Percent Change From Baseline in 28 Day Seizure Frequency at Week 16 | Levetiracetam | -57.28 | Full Range -100.0 to 276.9 | percent change | |
| Change From Baseline in the Proportion of 28-day Secondarily Generalized Tonic-clonic (SGTC) Seizure Rate to 28-day All Partial Seizure Rate at Week 16 | Pregabalin | Baseline (n=107, 111) | 39.41 | Standard Deviation 38.141 | percentage of all partial seizure/28days |
| Change From Baseline in the Proportion of 28-day Secondarily Generalized Tonic-clonic (SGTC) Seizure Rate to 28-day All Partial Seizure Rate at Week 16 | Levetiracetam | Baseline (n=107, 111) | 38.94 | Standard Deviation 35.870 | percentage of all partial seizure/28days |
| Change From Baseline in the Proportion of 28-day Secondarily Generalized Tonic-clonic (SGTC) Seizure Rate to 28-day All Partial Seizure Rate at Week 16 | Pregabalin | Change at Week 16 (n=102, 101) | 3.93 | Standard Deviation 30.158 | percentage of all partial seizure/28days |
| Change From Baseline in the Proportion of 28-day Secondarily Generalized Tonic-clonic (SGTC) Seizure Rate to 28-day All Partial Seizure Rate at Week 16 | Levetiracetam | Change at Week 16 (n=102, 101) | 6.33 | Standard Deviation 32.071 | percentage of all partial seizure/28days |
| Percentage of Participants Without Seizures | Pregabalin | All Partial Seizure | 19.9 | 95% Confidence Interval 14.4 to 25.4 | percentage of participants |
| Percentage of Participants Without Seizures | Levetiracetam | All Partial Seizure | 27.6 | 95% Confidence Interval 21.6 to 33.7 | percentage of participants |
| Percentage of Participants Without Seizures | Pregabalin | Simple Partial Seizure | 65.7 | 95% Confidence Interval 59.1 to 72.2 | percentage of participants |
| Percentage of Participants Without Seizures | Levetiracetam | Simple Partial Seizure | 66.2 | 95% Confidence Interval 59.8 to 72.6 | percentage of participants |
| Percentage of Participants Without Seizures | Pregabalin | Complex Partial Seizure | 49.3 | 95% Confidence Interval 42.3 to 56.2 | percentage of participants |
| Percentage of Participants Without Seizures | Levetiracetam | Complex Partial Seizure | 59.0 | 95% Confidence Interval 52.4 to 65.7 | percentage of participants |
| Percentage of Participants Without Seizures | Pregabalin | SGTC Seizure | 80.6 | 95% Confidence Interval 75.1 to 86.1 | percentage of participants |
| Percentage of Participants Without Seizures | Levetiracetam | SGTC Seizure | 79.0 | 95% Confidence Interval 73.5 to 84.6 | percentage of participants |
| Change From Baseline in Brief Psychiatric Rating Scale - Anchored (BPRS-A) Total and Core Score at Week 7, 10, 13, 16 and Follow-up | Pregabalin | Baseline: Total BPRS-A Score (n=253, 254) | 27.26 | Standard Error 0.55 | units on a scale |
| Change From Baseline in Brief Psychiatric Rating Scale - Anchored (BPRS-A) Total and Core Score at Week 7, 10, 13, 16 and Follow-up | Levetiracetam | Baseline: Total BPRS-A Score (n=253, 254) | 26.09 | Standard Error 0.56 | units on a scale |
| Change From Baseline in Brief Psychiatric Rating Scale - Anchored (BPRS-A) Total and Core Score at Week 7, 10, 13, 16 and Follow-up | Pregabalin | Baseline: Core BPRS-A Score (n=253, 254) | 5.18 | Standard Error 0.13 | units on a scale |
| Change From Baseline in Brief Psychiatric Rating Scale - Anchored (BPRS-A) Total and Core Score at Week 7, 10, 13, 16 and Follow-up | Levetiracetam | Baseline: Core BPRS-A Score (n=253, 254) | 5.01 | Standard Error 0.13 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00537238/results